Navigation Links
Original Drugs Pave the Way for Follow-on Biologics
Date:6/12/2013

MOUNTAIN VIEW, Calif., June 12, 2013 /PRNewswire/ --

WHEN:       

11:00 a.m. EDT on Tuesday, June 18, 2013

LOCATION:  

Online, with complimentary registration

SPEAKER:     

Healthcare Industry Manager Sandhya Kamath

With the impending patent expiries of biologic drugs, there is huge market potential for subsequent entry biologics. A strong integration of research and development with marketing is key to success.  This Technical Insights analyst briefing will highlight the latest technology advancements, as well as the trends shaping the future of this market.

Attend this webinar to:

  • Learn about the growth of follow-on biologics
  • Identify the drivers and restraints
  • Discover trends in technology development

This briefing will benefit pharmaceutical companies and specialty biotechnology firms by discussing emerging trends and providing forward-looking projections.

Supporting Quote

"By 2015, the follow-on biologics market is expected to transition to a stage of high growth," said Frost & Sullivan Healthcare Industry Manager Sandhya Kamath.  "With manufacturing advancements and regulatory guidelines falling into place, there is scope for more companies to venture into this space."

Supporting Resources

For more information about Frost & Sullivan's Technical Insights practice, please visit: http://www.technicalinsights.frost.com

Registration

  • To attend the briefing, email britni.myers@frost.com your full name, job title, company name, company telephone number, company email address and website, city, state and country.
  • Receive a recorded version of the briefing anytime by submitting the aforementioned contact details.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:        Gain access to visionary innovation

Contact:
Britni Myers
Frost & Sullivan
+1.210.477.8481
britni.myers@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
2. Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
3. Ophthalmic Drugs: World Market Prospects 2012-2022
4. Antithrombotic/Anticoagulant Drugs: World Market 2012-2022
5. INTAC™ Technology Combats Misuse of Extended Release Drugs
6. Contract Research Organizations Set to Experience Rapid Growth as Development Costs for New Drugs Continue to Rise
7. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
8. Bilcare and CSIR to Partner on nonClonableID Technology for Authentication of Drugs
9. Frost & Sullivan: Launch of New Classes of Oral Antidiabetic Drugs by 2014 will Uplift Prospects for the European Diabetes Therapeutics Market
10. Genitourinary Drugs: Technologies and Global Markets
11. Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLOs Seven Nosologies Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):